News >

Acalabrutinib Regimen Highly Active in MCL

Wayne Kuznar
Published: Wednesday, Dec 12, 2018

Tycel J. Phillips, MD

Tycel J. Phillips, MD

Adding the BTK inhibitor acalabrutinib (Calquence) to bendamustine and rituximab (Rituxan; BR) induced high overall response rates (ORRs) in both treatment-naïve and relapsed/refractory patients with mantle cell lymphoma (MCL), according to results from a phase Ib trial presented at the 2018 ASH Annual Meeting.

Findings from the ongoing, open-label study showed a 94% (n = 17) ORR among 18 treatment-naïve patients, including a complete response (CR) rate of 72% (n = 13) and a partial response (PR) rate of 22% (n = 4). The ORR was 85% (n = 17) among 20 relapsed/refractory patients, including a CR rate of 65% (n = 13) and a PR rate of 20% (n = 4). There was also 1 patients with stable disease in the relapse/refractory subgroup.

“Obviously, this is a small study, but the combination looks safe and effective,” said study investigator Tycel Phillips, MD, who presented the data at ASH.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication